IP Library Patent Application 16378177
Patent Application
App. No. 16/378,177

Compositions And Methods For Increasing Insulin Sensitivity

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/378,177
Abstract

Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.

Claims (19)

1 - 30 . (canceled)

31 . A method of treating a patient with a blood-glucose condition, the method comprising administering to a patient in need thereof a composition comprising a therapeutically effective amount of bupropion, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of naltrexone, or a pharmaceutically acceptable salt thereof.

32 . The method of claim 31 , wherein the amount of the bupropion or a pharmaceutically acceptable salt thereof is about 200 mg per day to about 400 mg per day.

33 . The method of claim 31 , wherein the amount of the naltrexone or a pharmaceutically acceptable salt thereof is about 25 mg per day to about 50 mg per day.

34 . The method of claim 31 , wherein the amount of the naltrexone or pharmaceutically acceptable salt thereof is about 25 mg per day to about 38 mg per day, and wherein the amount of the bupropion or pharmaceutically acceptable salt thereof is about 300 mg per day to about 400 mg per day.

35 . The method of claim 31 , wherein the blood-glucose condition is selected from diabetes, insulin resistance, hyperinsulinemia, impaired glucose metabolism, and hyperglycemia.

36 . The method of claim 32 , wherein the blood-glucose condition is Type 2 diabetes.

37 . The method of claim 31 , wherein the patient is obese.

38 . The method of claim 31 , wherein the patient is prediabetic.

39 . The method of claim 31 , further comprising obtaining a measurement of the subject's blood glucose level.

40 . The method of claim 39 , further comprising adjusting a dosage of the composition after obtaining the measurement of the subject's blood glucose level.

41 . The method of claim 31 , further comprising providing dietary instructions to the subject.

42 . The method of claim 31 , wherein the bupropion or pharmaceutically acceptable salt thereof is administered to the subject separately from the naltrexone or pharmaceutically acceptable salt thereof.

43 . The method of claim 31 , wherein the amount of bupropion or pharmaceutically acceptable salt thereof is in a divided dose for administration twice a day, and wherein the amount of naltrexone or pharmaceutically acceptable salt thereof is in a divided dose for administration twice a day.

44 . The method of claim 31 , wherein the composition comprises a controlled release formulation.

45 . The method of claim 43 , wherein at least one of the naltrexone or pharmaceutically acceptable salt thereof and the bupropion or pharmaceutically acceptable salt thereof is in a sustained release formulation.

46 . The method of claim 44 , wherein each of the naltrexone or pharmaceutically acceptable salt thereof and the bupropion or pharmaceutically acceptable salt thereof is in a sustained release formulation.

47 . The method of claim 31 , wherein the naltrexone or pharmaceutically acceptable salt thereof and the bupropion or pharmaceutically acceptable salt thereof are in a single oral dosage form.

48 . The method of claim 46 , wherein the single oral dosage form is in the form of a tablet, pill, or capsule.

Assignments (4)
SECURITY INTEREST Recorded Dec 19, 2019
From: CURRAX PHARMACEUTICALS LLC; NALPROPION PHARMACEUTICALS LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 051377/0958 →
CHANGE OF NAME Recorded Oct 17, 2019
From: NALPROPION PHARMACEUTICALS, INC.
To: NALPROPION PHARMACEUTICALS LLC
Reel/Frame 050750/0497 →
RELEASE OF SECURITY INTEREST Recorded Sep 27, 2019
From: WILMINGTON SAVINGS FUND SOCIETY, FSB
To: NALPROPION PHARMACEUTICALS, INC.
Reel/Frame 050520/0149 →
SECURITY INTEREST Recorded May 6, 2019
From: NALPROPION PHARMACEUTICALS, INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 049092/0156 →